Four-week short chain fructo-oligosaccharides ingestion leads to increasing fecal bifidobacteria and cholesterol excretion in healthy elderly volunteers

Nutrition Journal - Tập 6 - Trang 1-7 - 2007
Yoram Bouhnik1, Lotfi Achour2, Damien Paineau3, Michel Riottot4, Alain Attar1, Francis Bornet3
1Pôle des Maladies de l'Appareil Digestif (PMAD), Service de Gastroentérologie et d'Assistance Nutritive, Hôpital Beaujon, Clichy Cedex, France
2Institut Supérieur de Biotechnologie, Monastir
3Nutri-Health SA, Immeuble Ampère, Rueil-Malmaison Cedex, France
4Laboratoire de Physiologie de la Nutrition, Université Paris Sud, ORSAY Cedex, France

Tóm tắt

Short-chain fructo-oligosaccharides (scFOS) are increasingly used in human diet for their prebiotic properties. We aimed at investigating the effects of scFOS ingestion on the colonic microflora and oro-fecal transit time in elderly healthy humans. Stools composition, oro-fecal transit time, and clinical tolerance were evaluated in 12 healthy volunteers, aged 69 ± 2 yrs, in three consecutive periods: basal period (2 weeks), scFOS (Actilight®) ingestion period (8 g/d for 4 weeks) and follow-up period (4 weeks). Two-way ANOVA, with time and treatment as factors, was used to compare the main outcome measures between the three periods. Fecal bifidobacteria counts were significantly increased during the scFOS period (9.17 ± 0.17 log cfu/g vs 8.52 ± 0.26 log cfu/g during the basal period) and returned to their initial values at the end of follow-up (8.37 ± 0.21 log cfu/g; P < 0.05). Fecal cholesterol concentration increased during the scFOS period (8.18 ± 2.37 mg/g dry matter vs 2.81 ± 0.94 mg/g dry matter during the basal period) and returned to the baseline value at the end of follow-up (2.87 ± 0.44 mg/g dry matter; P < 0.05). Fecal pH tended to decrease during scFOS ingestion and follow-up periods compared to the basal period (P = 0.06). Fecal bile acids, stool weight, water percentage, and oro-fecal transit time did not change throughout the study. Excess flatus and bloating were significantly more frequent during scFOS ingestion when compared to the basal period (P < 0.05), but the intensity of these symptoms was very mild. Four-week 8 g/d scFOS ingestion is well tolerated and leads to a significant increase in fecal bifidobacteria in healthy elderly subjects. Whether the change in cholesterol metabolism found in our study could exert a beneficial action warrants further studies.

Tài liệu tham khảo

Hirayama M, Sumi N, Hidaka H: Purification and properties of fructo-oligosaccharides producing beta-fructofuranosidase from Aspergillus niger ATCC 20611. Agric Biol Chem ; :. 1989, 53: 667-673.

Alles MS, Hautvast JG, Nagengast FM, Hartemink R, Van Laere KM, Jansen JB: Fate of fructo-oligosaccharides in the human intestine. Br J Nutr. 1996, 76: 211-221. 10.1079/BJN19960026.

Molis C, Flourie B, Ouarne F, Gailing MF, Lartigue S, Guibert A, Bornet F, Galmiche JP: Digestion, excretion, and energy value of fructooligosaccharides in healthy humans. Am J Clin Nutr. 1996, 64: 324-328.

Gibson GR, Roberfroid MB: Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995, 125: 1401-1412.

Bouhnik Y, Raskine L, Simoneau G, Vicaut E, Neut C, Flourié B, Brouns F, Bornet F: The capacity of nondigestible carbohydrates to stimulate fecal bifidobacteria in healthy humans: a double-blind, randomized, placebo-controlled, parallel-group, dose-response relation study. Am J Clin Nutr. 2004, 6: 1658-1664.

Bouhnik Y, Vahedi K, Achour L, Attar A, Salfati J, Pochart P, Marteau P, Flourie B, Bornet F, Rambaud JC: Short-chain fructo-oligosaccharide administration dose-dependently increases fecal bifidobacteria in healthy humans. J Nutr. 1999, 129: 113-116.

Bouhnik Y, Raskine L, Simoneau G, Paineau D, Bornet F: The capacity of short-chain fructo-oligosaccharides to stimulate faecal bifidobacteria: a dose-response relationship study in healthy humans. Nutr J. 2006, 5: 8-10.1186/1475-2891-5-8.

Roberfroid MB: Health benefits of non-digestible oligosaccharides. Adv Exp Med Biol. 1997, 427: 211-219.

Koo M, Rao AV: Long-term effect of Bifidobacteria and Neosugar on precursor lesions of colonic cancer in CF1 mice. Nutr Cancer. 1991, 16: 249-257.

Singh J, Rivenson A, Tomita M, Shimamura S, Ishibashi N, Reddy BS: Bifidobacterium longum, a lactic acid-producing intestinal bacterium inhibits colon cancer and modulates the intermediate biomarkers of colon carcinogenesis. Carcinogenesis. 1997, 18: 833-841. 10.1093/carcin/18.4.833.

Challa A, Rao DR, Chawan CB, Shackelford L: Bifidobacterium longum and lactulose suppress azoxymethane-induced colonic aberrant crypt foci in rats. Carcinogenesis. 1997, 18: 517-521. 10.1093/carcin/18.3.517.

Nair PP: Role of bile acids and neutral sterols in carcinogenesis. Am J Clin Nutr. 1988, 48: 768-774.

Marteau P, Pochart P, Flourie B, Pellier P, Santos L, Desjeux JF, Rambaud JC: Effect of chronic ingestion of a fermented dairy product containing Lactobacillus acidophilus and Bifidobacterium bifidum on metabolic activities of the colonic flora in humans. Am J Clin Nutr. 1990, 52: 685-688.

El Oufir L, Flourie B, Bruley V, Barry JL, Cloarec D, Bornet F, Galmiche JP: Relations between transit time, fermentation products, and hydrogen consuming flora in healthy humans. Gut. 1996, 38: 870-877. 10.1136/gut.38.6.870.

Cummings JH, Bingham SA, Heaton KW, Eastwood MA: Fecal weight, colon cancer risk, and dietary intake of nonstarch polysaccharides (dietary fiber). Gastroenterology. 1992, 103: 1783-1789.

Miller K, Waye JD: Colorectal polyps in the elderly: what should be done?. Drugs Aging. 2002, 19: 393-404. 10.2165/00002512-200219060-00001.

Woodmansey EJ, McMurdo ME, Macfarlane GT, Macfarlane S: Comparison of compositions and metabolic activities of fecal microbiotas in young adults and in non-antibiotic-treated elderly subjects. Appl Env Microbiol. 2004, 70: 6113-6122. 10.1128/AEM.70.10.6113-6122.2004.

Finegold SM, Sutter VL, Mathisen GE: Normal indigenous intestinal flora. Human intestinal microflora in health and disease. Edited by: Hentges DJ. 1983, New York, Academic Press, 3-31.

Woodmansey EJ: Intestinal bacteria and ageing. J Appl Microbiol. 2007, 102: 1178-1186. 10.1111/j.1365-2672.2007.03400.x.

Bunout D, Hirsch S, Pia de la Maza M, Munoz C, Haschke F, Steenhout P, Klassen P, Barrera G, Gattas V, Petermann M: Effects of prebiotics on the immune response to vaccination in the elderly. JPEN J Parenter Enteral Nutr. 2002, 26: 372-376.

Hamilton-Miller JM: Probiotics and prebiotics in the elderly. Postgrad Med J. 2004, 80: 447-451. 10.1136/pgmj.2003.015339.

Mitsuoka T, Hidaka H, Eida T: Effect of fructo-oligosaccharides on intestinal microflora. Nahrung. 1987, 31: 427-436. 10.1002/food.19870310528.

Cummings JH, Wiggins HS: Transit through the gut measured by analysis of a single stool. Gut. 1976, 17: 219-223. 10.1136/gut.17.3.219.

Riottot M, Olivier P, Huet A, Caboche JJ, Parquet M, Khallou J, Lutton C: Hypolipidemic effects of beta-cyclodextrin in the hamster and in the genetically hypercholesterolemic Rico rat. Lipids. 1993, 28: 181-188. 10.1007/BF02536637.

Stempfel RSJ, Sidbury JBJ: Studies with the hydroxysteroid dehydrogenases. i. a simplified method for the enzymatic estimation of 3- and 17-hydroxysteroids. J Clin Endocrinol Metab. 1964, 24: 367-374.

Tuohy KM, Kolida S, Lustenberger AM, Gibson GR: The prebiotic effects of biscuits containing partially hydrolysed guar gum and fructo-oligosaccharides--a human volunteer study. Br J Nutr. 2001, 86: 341-348.

Gibson GR, Beatty ER, Wang X, Cummings JH: Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology. 1995, 108: 975-982. 10.1016/0016-5085(95)90192-2.

Bouhnik Y, Flourie B, Riottot M, Bisetti N, Gailing MF, Guibert A, Bornet F, Rambaud JC: Effects of fructo-oligosaccharides ingestion on fecal bifidobacteria and selected metabolic indexes of colon carcinogenesis in healthy humans. Nutr Cancer. 1996, 26: 21-29.

Bartosch S, Woodmansey EJ, Paterson JCM, McMurdo ME, Macfarlane GT: Microbiological effects of consuming a synbiotic containing Bifidobacterium bifidum, Bifidobacterium lactis, and oligofructose in elderly persons, determined by real-time polymerase chain reaction and cunting of viable bacteria. Clin Infect Dis. 2005, 40: 28-37. 10.1086/426027.

Ito M, Deguchi Y, Miyamori A: Effects of administration of galacto-oligosaccharides on the human faecal microflora, stool weight and abdominal sensation. Microb Ecol Healt Dis. 1990, 3: 285-292.

Picard C, Fioramonti J, Francois A, Robinson T, Neant F, C M: Review article: bifidobacteria as probiotic agents -- physiological effects and clinical benefits. Aliment Pharmacol Ther. 2005, 22: 495-512. 10.1111/j.1365-2036.2005.02615.x.

Eyssen H, Parmentier G: Biohydrogenation of sterols and fatty acids by the intestinal microflora. Am J Clin Nutr. 1974, 27: 1329-1340.

Hill MJ: Faecal steroids in the etiology of large bowel cancer. The Bile Acids. Edited by: Nair PP KD. 1976, New York, Plenum, 169-200.

Andrieux C, Gadelle D, Leprince C, Sacquet E: Effects of some poorly digestible carbohydrates on bile acid bacterial transformations in the rat. Br J Nutr. 1989, 62: 103-119. 10.1079/BJN19890011.

Hori T, Matsumoto K, Sakaitani Y, Sato M, Morotomi M: Effect of dietary deoxycholic acid and cholesterol on fecal steroid concentration and its impact on the colonic crypt cell proliferation in azoxymethane-treated rats. Cancer Lett. 1998, 124: 79-84. 10.1016/S0304-3835(97)00452-7.

Narisawa T, Magadia NE, Weisburger JH, Wynder EL: Promoting effect of bile acids on colon carcinogenesis after intrarectal instillation of N-methyl-N'-nitro-N-nitrosoguanidine in rats. J Natl Cancer Inst. 1974, 53: 1093-1097.

Breuer NF, Goebell H: Bile acids and cancer of the large bowel. Dig Dis. 1987, 5: 65-77.

Pereira DIA, Gibson GR: Cholesterol Assimilation by Lactic Acid Bacteria and Bifidobacteria Isolated from the Human Gut. Appl Environ Microbiol. 2002, 68: 4689-4693. 10.1128/AEM.68.9.4689-4693.2002.

Thông tin
Thông tin xuất bản

Nutrition Journal

Tập 6

1-7

Thông tin tác giả